Mauro Bologna

Prof. Mauro Bologna


Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in Urology
Verified
Journal Article
Closed access
GDGiulia D’amati
Giulia D’amati
CGCira R.T di Gioia
Cira R.T di Gioia
MBMauro Bologna
Mauro Bologna
DGDaniela Giordano
Daniela Giordano
MGMauro Giorgi
Mauro Giorgi
Emmanuele A. JanniniEmmanuele A. Jannini
Emmanuele A. Jannini

1 July 2006 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
Nadia RucciNadia Rucci
Nadia Rucci
IRIrene Recchia
Irene Recchia
Adriano  AngelucciAdriano Angelucci
Adriano Angelucci
MAMarina Alamanou
Marina Alamanou
ANDREA DEL FATTOREANDREA DEL FATTORE
ANDREA DEL FATTORE
Anna Maria TetiAnna Maria Teti
Anna Maria Teti
C-Src is a proto-oncogene, belonging to the nonreceptor protein kinases family, which plays a prominent role in carcinogenesis. In this study, we tested the hypothesis that c-Src could promote breast cancer metastasis acting on several cell types and that pharmacological disruption of its kinase activity could be beneficial for the treatment of metastases. Female BALB/c-nu/nu mice were subjected to intracardiac injection of the human breast cancer cells MDA-MB-231 (MDA-231), which induced prominent bone and visceral metastases. These were pharmacologically reduced by treatment with the c-Src inhibitor [7-{4-[2-(2-methoxy-ethylamino-ethoxy]-phenyl}-5-(3-methoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine] CGP76030 (100 mg/kg/day p.o.), resulting in decreased morbidity and lethality. Metastases were more severe in mice injected with MDA-231 cells stably transfected with wild-type c-Src (MDA-231-SrcWT), whereas transfection in injected cells of a c-Src kinase-dead dominant-negative construct (MDA-231-SrcDN) resulted in reduced morbidity, lethality, and incidence of metastases similar to the mice treated with the inhibitor. An analogous beneficial effect of c-Src inhibition was observed in subcutaneous and intratibial implanted tumors. In vitro, c-Src suppression reduced MDA-231 cell aggressiveness. It also impaired osteoclast bone resorption both directly and by reducing expression by osteoblasts of the osteoclastogenic cytokines interleukin-1β and interleukin-6, whereas parathyroid hormone-related peptide was not implicated. c-Src was also modestly but consistently involved in the enhancement of endothelial cell proliferation in vitro and angiogenesis in vivo. In conclusion, we propose that c-Src disruption affects the metastatic process and thus is a therapeutic target for the treatment of breast cancer.

1 August 1981 in Nature
Verified
Journal Article
Closed access
RDR. Dulbecco
R. Dulbecco
MUM. Unger
M. Unger
MBMauro Bologna
Mauro Bologna
HBH. Battifora
H. Battifora
PSP. Syka
P. Syka
SOS. Okada
S. Okada

12 August 2004 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MMMarina Maggiora
Marina Maggiora
MBMauro Bologna
Mauro Bologna
MCMaria Paola Cerù
Maria Paola Cerù
LPLaura Possati
Laura Possati
Adriano  AngelucciAdriano Angelucci
Adriano Angelucci
RCRosa Angela Canuto
Rosa Angela Canuto
Both n‐6 and n‐3 polyunsaturated fatty acids are dietary fats important for cell function, being involved in several physiologic and pathologic processes, such as tumorigenesis. Linoleic acid and conjugated linoleic acid, its geometrical and positional stereoisomer, were tested on several human tumor cell lines originating from different tissues and with different degrees of malignancy. This was to provide the widest possible view of the impact of dietary lipids on tumor development. While linoleic acid exerted different effects, ranging from inhibitory to neutral, even promoting growth, conjugated linoleic acid inhibited growth in all lines tested and was particularly effective against the more malignant cells, with the exception of mammary tumor cells, in which behavior was the opposite, the more malignant cell line being less affected. The inhibitory effect of conjugated linoleic acid on growth may be accompanied by different contributions from apoptosis and necrosis. The effects of conjugated linoleic acid on growth or death involved positive or negative variations in PPARs. The important observation is that a big increase of PPARα protein occurred in cells undergoing strong induction of apoptosis, whereas PPARβ/δ protein decreased. Although PPARα and PPARβ/δ seem to be correlated to execution of the apoptotic program, the modulation of PPARγ appears to depend on the type of tumor cell, increasing as protein content, when inhibition of cell proliferation occurred. In conclusion, CLA may be regarded as a component of the diet that exerts antineoplastic activity and its effect may be antiproliferative or pro‐apoptotic.

5 March 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PSPatrizia Sanità
Patrizia Sanità
MCMattia Capulli
Mattia Capulli
Anna Maria TetiAnna Maria Teti
Anna Maria Teti
GGGiuseppe Paradiso Galatioto
Giuseppe Paradiso Galatioto
CVCarlo Vicentini
Carlo Vicentini
Adriano  AngelucciAdriano Angelucci
Adriano Angelucci
Background: Cancer cell adopts peculiar metabolic strategies aimed to sustain the continuous proliferation in an environment characterized by relevant fluctuations in oxygen and nutrient levels. Monocarboxylate transporters MCT1 and MCT4 can drive such adaptation permitting the transport across plasma membrane of different monocarboxylic acids involved in energy metabolism. Methods: Role of MCTs in tumor-stroma metabolic relationship was investigated in vitro and in vivo using transformed prostate epithelial cells, carcinoma cell lines and normal fibroblasts. Moreover prostate tissues from carcinoma and benign hypertrophy cases were analyzed for individuating clinical-pathological implications of MCT1 and MCT4 expression. Results: Transformed prostate epithelial (TPE) and prostate cancer (PCa) cells express both MCT1 and MCT4 and demonstrated variable dependence on aerobic glycolysis for maintaining their proliferative rate. In glucose-restriction the presence of L-lactate determined, after 24 h of treatment, in PCa cells the up-regulation of MCT1 and of cytochrome c oxidase subunit I (COX1), and reduced the activation of AMP-activated protein kinase respect to untreated cells. The blockade of MCT1 function, performed by si RNA silencing, determined an appreciable antiproliferative effect when L-lactate was utilized as energetic fuel. Accordingly L-lactate released by high glycolytic human diploid fibroblasts WI-38 sustained survival and growth of TPE and PCa cells in low glucose culture medium. In parallel, the treatment with conditioned medium from PCa cells was sufficient to induce glycolytic metabolism in WI-38 cells, with upregulation of HIF-1a and MCT4. Co-injection of PCa cells with high glycolytic WI-38 fibroblasts determined an impressive increase in tumor growth rate in a xenograft model that was abrogated by MCT1 silencing in PCa cells. The possible interplay based on L-lactate shuttle between tumor and stroma was confirmed also in human PCa tissue where we observed a positive correlation between stromal MCT4 and tumor MCT1 expression. Conclusions: Our data demonstrated that PCa progression may benefit of MCT1 expression in tumor cells and of MCT4 in tumor-associated stromal cells. Therefore, MCTs may result promising therapeutic targets in different phases of neoplastic transformation according to a strategy aimed to contrast the energy metabolic adaptation of PCa cells to stressful environments.

1 April 2009 in The American Journal of Pathology
Verified
Journal Article
Closed access
MTMaria Letizia Taddei
Maria Letizia Taddei
MPMatteo Parri
Matteo Parri
Adriano  AngelucciAdriano Angelucci
Adriano Angelucci
BOBarbara Onnis
Barbara Onnis
Francesca BianchiniFrancesca Bianchini
Francesca Bianchini
PCPaola Chiarugi
Paola Chiarugi